This paper explores the long term effect of cannabis on mental health. These studies prove a clear correlation between cannabis use and mental health disorders, however, none of the them conclude that cannabis is the sole cause of the development of the disorders. such as, schizophrenia, bi-polar disorder and depression.
Keywords: Delta-9-tetrahydrocannabinol (∆9-THC), Cannabidiol (CBN), Cannabinol (CBC), schizophrenia, depression, bi-polar disorder
Table of Contents
1. Introduction
2. Cannabis and Schizophrenia
3. Cannabis and Depression
4. Conclusion
Objectives & Key Themes
This paper aims to investigate the complex relationship between cannabis use and its long-term effects on mental health, specifically examining its correlations with schizophrenia and depression while critically distinguishing between correlation and causation.
- The role of Delta-9-tetrahydrocannabinol (Δ9-THC) as a psychoactive factor in mental health disorders.
- The potential antipsychotic properties of Cannabidiol (CBD) and its role in symptom management.
- Critical analysis of longitudinal follow-up studies regarding cannabis and schizophrenia risk.
- Evaluation of contradictory evidence regarding cannabis use and depressive symptoms.
- The impact of regulatory limitations on experimental research concerning cannabis.
Excerpt from the Book
The Effect of Cannabis on Schizophrenia and Depression
Cannabis has been associated with schizophrenia and depression for a very long time. There are numerous studies that show correlation between cannabis and schizophrenia and depression. There are also studies that contradict this long time association and illustrate an inverse correlation between cannabis and schizophrenia and depression (Denson & Earlywine 2006). This paper reveals the common problems with mistaking correlation and causation. As stated in an interview with Pers Hambric (2011) “Just because two events occur at the same time does not imply that they share a cause and effect relationship”.
Cannabis use is frequent among schizophrenic patients. Delta-9-tetrahydrocannabinol (∆9-THC) is the psychoactive compound of cannabis that allegedly causes the development of schizophrenia (Zammit S, Allebeck P, Andreasson S, Lundberg I, and Lewis G, 2002). Researchers are still unsure whether or not this psychoactive compound is the sole cause of the development of schizophrenia or a form of a schizophreniform disorder. There is research that suggests a person that is genetically pre-determined to develop schizophrenia or form of a schizophreniform disorder may be more inclined to use cannabis (Arseneault et al. 2002).
Summary of Chapters
1. Introduction: Introduces the research scope, highlighting the two primary cannabinoids (THC and CBD) and the central challenge of distinguishing correlation from causation in mental health studies.
2. Cannabis and Schizophrenia: Reviews clinical trials and longitudinal studies, such as the Swedish conscripts study, to analyze the link between THC exposure and psychotic symptoms, as well as the antipsychotic potential of CBD.
3. Cannabis and Depression: Examines contradictory research, including Australian cohort studies and online surveys, which demonstrate that the relationship between cannabis and depression is not as straightforward as once hypothesized.
4. Conclusion: Summarizes the current state of research, noting that due to strict legal regulations and conflicting empirical evidence, a definitive causal link between cannabis and these mental health disorders remains unproven.
Keywords
Delta-9-tetrahydrocannabinol, Δ9-THC, Cannabidiol, CBD, cannabis, mental health, schizophrenia, depression, psychosis, correlation, causation, antipsychotic, cannabinoids, longitudinal study, clinical trial
Frequently Asked Questions
What is the core focus of this research paper?
This paper examines the long-term impact of cannabis use on mental health, specifically focusing on the debated links between cannabis consumption and the development of schizophrenia and depression.
What are the central thematic areas discussed?
The study centers on the psychoactive effects of Δ9-THC, the potential therapeutic benefits of Cannabidiol (CBD), and the methodological pitfalls of confusing correlation with causation in psychiatric research.
What is the primary goal of the author?
The goal is to provide a critical overview of current literature to determine whether a clear causal relationship exists between cannabis use and the onset of mental health disorders.
Which scientific methodologies are highlighted?
The paper reviews a variety of methods, including longitudinal follow-up studies, individual case studies, clinical trials, and large-scale online surveys.
What topics are covered in the main body?
The main body details specific studies on schizophrenia—such as the Swedish conscript cohort—and depression, while contrasting the psychotic effects of THC with the antipsychotic properties of CBD.
What are the key terms that define this work?
Key terms include Δ9-THC, Cannabidiol (CBD), schizophrenia, depression, correlation vs. causation, and cannabinoid-based treatments.
How does the study address the role of CBD in schizophrenia?
The paper presents evidence from case studies and clinical trials indicating that CBD may act as an effective antipsychotic, offering a safer alternative with fewer side effects compared to traditional medication.
Why is it difficult to draw firm conclusions about cannabis and mental health?
Due to the illegality of cannabis in many jurisdictions, high-quality, government-sanctioned experimental research is restricted, and many observational studies fail to control for external variables like pre-existing psychological vulnerability or the use of other substances.
- Quote paper
- Christopher Neuhaus (Author), 2011, Cannabis and Mental Health, Munich, GRIN Verlag, https://www.hausarbeiten.de/document/210777
